Literature DB >> 2528353

Serum IgG antibodies to C1q in hypocomplementemic urticarial vasculitis syndrome.

J J Wisnieski1, G B Naff.   

Abstract

Urticaria, angioedema, and arthritis are cardinal features of hypocomplementemic urticarial vasculitis syndrome (HUVS). Considered to be an immune complex-mediated disorder, HUVS has been differentiated from systemic lupus erythematosus (SLE), based on its clinical manifestations and the C1q precipitin (C1q-p) reaction, which is manifested as gel precipitation of C1q by a small percentage of HUVS IgG molecules. This phenomenon has been attributed to an Fc region abnormality, and the responsible IgG molecules are said to possess C1q-p activity. We purified IgG from 4 HUVS patients and confirmed that HUVS IgG contains C1q binding activity. F(ab')2 fragments from these patients also bound to C1q, as measured by 2 different C1q binding methods at physiologic ionic strength; HUVS IgG Fc fragments did not bind to C1q. Preincubation of HUVS F(ab')2 fragments with antibody to human F(ab')2 prevented subsequent binding to C1q. We conclude that IgG antibodies to C1q are present in HUVS serum, and it is likely that these antibodies are C1q-p. Because the clinical manifestations of HUVS and the presence of anti-C1q antibodies have been described in patients with SLE, our findings support the concept that HUVS is an autoimmune syndrome related to SLE.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2528353     DOI: 10.1002/anr.1780320910

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

1.  Meningococcal meningitis in a patient with urticarial vasculitis: is there a link?

Authors:  Hana Alachkar; Faieza Qasim; Yasmeen Ahmad; Matthew Helbert
Journal:  J Clin Pathol       Date:  2007-10       Impact factor: 3.411

Review 2.  Urticarial vasculitis and syndromes in association with connective tissue diseases.

Authors:  R A Asherson; R Sontheimer
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

3.  Urticarial skin lesions and polymyositis due to lymphocytic vasculitis.

Authors:  N L Kao; H J Zeitz
Journal:  West J Med       Date:  1995-02

Review 4.  Are anti-C1q antibodies different from other SLE autoantibodies?

Authors:  Matthew C Pickering; Marina Botto
Journal:  Nat Rev Rheumatol       Date:  2010-04-27       Impact factor: 20.543

5.  Recurrent angioedema and urticaria.

Authors:  P C Bishop; J J Wisnieski; J Christensen
Journal:  West J Med       Date:  1993-11

6.  Hypocomplementemic urticarial vasculitis in systemic lupus erythematosus.

Authors:  Min Young Her; Joo Yeon Song; Dong Yook Kim
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

7.  Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus.

Authors:  V Michael Holers
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

8.  IgG autoantibodies to C1q do not detectably influence complement activation in vivo and in vitro in systemic lupus erythematosus.

Authors:  C E Siegert; M R Daha; S Lobatto; E A van der Voort; F C Breedveld
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

9.  Anti-C1q in systemic lupus erythematosus.

Authors:  G Stojan; M Petri
Journal:  Lupus       Date:  2016-07       Impact factor: 2.911

Review 10.  An approach to the patient with urticaria.

Authors:  S J Deacock
Journal:  Clin Exp Immunol       Date:  2008-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.